Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">BACKGROUND</h3><p><strong>:</strong> Visceral obesity and fatty liver are prevalent in postmenopausal women. The stilbene-rich extract of <em>Cajanus cajan</em> (L.) Millsp. has been reported to prevent ovariectomy-induced and diet-induced weight gain in animal models, and stilbenoids from <em>C. cajan</em> are thought to have the potential to prevent postmenopausal obesity and fatty liver.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">PURPOSE</h3><p><strong>:</strong> Cajanolactone A (CLA) is the main stilbenoid from <em>C. cajan</em> with osteoblastogenic promoting activity. This study investigated the potential of CLA to prevent postmenopausal obesity and fatty liver. Underlying mechanisms were also investigated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">METHOD</h3><p><strong>:</strong> Ovariectomized C57BL/6 mice fed a regular diet were used as mimics of postmenopausal women and given 10, 20, or 40 mg/kg/d of CLA, 0.1 mg/kg/d of estradiol valerate (EV, positive control), or vehicle (OVX) orally for 16 weeks. Mice of the same age subjected to a sham operation were used as control (Sham). Body weights were recorded every 2 weeks for 16 weeks. Body compositions were analyzed via micro-CT. Serum levels of lipids, adipocytokines and aminotransferases were measured using the relevant kits. mRNA levels of genes of interest were detected by RT-qPCR. Proteomic study of perigonadal white adipose tissue (pWAT) was performed using tandem-mass-tags-based proteomic technology combined with Parallel-Reaction-Monitoring (PRM) validation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">RESULTS</h3><p><strong>:</strong> CLA showed potential equivalent to that of EV to prevent ovariectomy-induced overweight, obesity, dyslipidemia, liver steatosis and liver dysfunction, but did not prevent uterine atrophy. In the liver, CLA significantly inhibited ovariectomy-induced upregulation in expression of lipogenic genes <em>SREBP-1c</em> and <em>ChREBP</em>, and stimulated the mRNA expression of apolipoprotein B gene <em>ApoB</em>. In pWAT, CLA reversed, or partially reversed ovariectomy-induced downregulation in the expression of a number of metabolism- and mitochondrial-function-related proteins, including Ndufa3, Pcx, Pdhb, Acly, Acaca, Aldh2, Aacs and Echs1. In addition, ovariectomy-inhibited mRNA expression of <em>Pdhb, Aacs, Acsm5, Echs1,</em> and <em>Aldh2</em> genes in pWAT was also reversed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">CONCLUSION</h3><p><strong>:</strong> CLA was demonstrated to be a potential non-estrogen-like drug candidate for prevention of postmenopausal obesity and fatty liver. The underlying mechanism might involve the inhibition of lipogenesis and promotion of triglycerides output in the liver, and the promotion of metabolism and mitochondrial functions of visceral white adipose tissue.</p>

Cajanolactone A from Cajanus cajan Promoted Osteoblast Differentiation in Human Bone Marrow Mesenchymal Stem Cells via Stimulating Wnt/LRP5/β-Catenin Signaling

Effects of water extract of Cajanus cajan leaves on differentiation and function of primary osteoblasts and osteoclasts in vitro

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways (vol 234, pg 11792, 2019)

Cajanolactone A, a stilbenoid from cajanus cajan, prevents ovariectomy-induced obesity and liver steatosis in mice fed a regular diet

Cajanolactone A, a stilbenoid from Cajanus cajan, inhibits energy intake and lipid synthesis/storage, and promotes energy expenditure in ovariectomized mice

Curculigoside Regulates Proliferation, Differentiation, and Pro-Inflammatory Cytokines Levels in Dexamethasone-Induced Rat Calvarial Osteoblasts.

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

N-acetyl-L-cysteine enhances the osteogenic differentiation and inhibits the adipogenic differentiation through up regulation of Wnt 5a and down regulation of PPARG in bone marrow stromal cells

A natural agent, 5-deoxycajanin, mitigates estrogen-deficiency bone loss via modulating osteoclast-osteoblast homeostasis

17-Hydroxy-jolkinolide A Inhibits Osteoclast Differentiation Through Suppressing the Activation of NF-κB and MAPKs

Casticin promotes osteogenic differentiation of bone marrow stromal cells and improves osteoporosis in rats by regulating nuclear factor-κB/mitogen-activated protein kinase

Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl‐Induced Nf‐κb and Nfatc1 Activities

Enhanced Efficiency of Calcium-Derived Oleoyl Serine on Osteoporosis Via Wnt/β-catenin Pathway.

Strontium Ranelate Promotes Chondrogenesis Through Inhibition of the Wnt/β-catenin Pathway

Calycosin-7-O-β-d-glucopyranoside stimulates osteoblast differentiation through regulating the BMP/WNT signaling pathways

Docking study and antiosteoporosis effects of a dibenzylbutane lignan isolated from Litsea cubeba targeting Cathepsin K and MEK1

Angelica Sinensis Extract Inhibits RANKL-mediated Osteoclastogenesis by Down-Regulated the Expression of NFATc1 in Mouse Bone Marrow Cells

Oleanolic Acid Enhances Mesenchymal Stromal Cell Osteogenic Potential by Inhibition of Notch Signaling

Baicalin positively regulates osteoclast function by activating MAPK/Mitf signalling